Search | Clinical Trials Finder

Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Duke University; Other
Eligibility: 0 Years to 20 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 49
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more

Conditions: Postpartum Hemorrhage, Immediate Postpartum Hemorrhage, Hemorrhage, Postpartum
Interventions: KOKO Device; Device
Lead sponsor: KOKO Medical Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 17
States / cities: Birmingham, Alabama • Newark, Delaware • Miami, Florida + 12 more

Conditions: Abnormal Uterine Bleeding (AUB), Endometrial Cancer, Atypical Endometrial Hyperplasia, Endometrial Hyperplasia With Atypia, Endometrial Intraepithelial Neoplasia
Interventions: Not listed
Lead sponsor: Exact Sciences Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 4,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Sarasota, Florida • Scarborough, Maine • Murfreesboro, Tennessee + 1 more

Conditions: Abnormal Uterine Bleeding
Interventions: Blood management, Usual care; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Menorrhagia
Interventions: Genesys HTA; Device
Lead sponsor: Minerva Surgical, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,014 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 19
States / cities: San Diego, California • Newark, Delaware • Athens, Georgia + 16 more

Conditions: Postpartum Hemorrhage, Postpartum Preeclampsia, Postpartum Sepsis, Postpartum Depression, Patient Empowerment, Patient Education, Postpartum Care
Interventions: Video Education; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Menstrual Migraines, Menstrual Bleeding, Menstrual Spotting
Interventions: Estradiol or Placebo; Drug
Lead sponsor: Scott and White Hospital & Clinic; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Analgesia, Obstetrical, Coagulation Defect; Postpartum, Nonsteroidals (NSAIDs)Toxicity, Postpartum Hemorrhage, Postoperative Pain, Ketorolac Adverse Reaction, Blood Loss, Postoperative
Interventions: Ketorolac Tromethamine 30 MG/ML, Placebos; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obstetric Labor Complications, Hemorrhage, Complications; Cesarean Section
Interventions: Blood Draw; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Iron Deficiency Anemia Treatment, Iron Deficiency, Iron Deficiency (Without Anemia)
Interventions: FeoSol Original Iron Supplement Tablets, 21st Century Gelatin Capsules; Dietary Supplement
Lead sponsor: Purdue University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Post Partum Haemorrhage, Maternal Care Patterns, High Risk Pregnancy
Interventions: Oli is a non-invasive, wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding; Device
Lead sponsor: Baymatob Operations Pty Ltd; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Denver, Colorado • Baton Rouge, Louisiana • New York, New York + 2 more

Conditions: Menorrhagia
Interventions: Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills, Naproxen sodium pills, NovaSure® Radiofrequency Endometrial Ablation; Drug · Device
Lead sponsor: Abimbola Famuyide; Other
Eligibility: 30 Years to 55 Years · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Bleeding, Implants, Breakthrough Bleeding
Interventions: Tamoxifen, Placebo, Tamoxifen (open label); Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 15 Years to 45 Years · Female only
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Heavy Menstrual Bleeding, Fibroid Uterus
Interventions: Groups 1 and 2 myomectomy and uterine artery embolization, respectively, are surgical/procedure, Elagolix Oral Product; Other · Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Postpartum Hemorrhage
Interventions: Initiation of standard postpartum oxytocin immediately following fetal shoulder delivery, Initiation of standard postpartum oxytocin immediately following placenta delivery, Saline Placebo; Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Uterine Atony, Uterine Atony With Hemorrhage, Postpartum Hemorrhage, Cesarean Section Complications
Interventions: Calcium chloride, Saline placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Pacifica, California

Conditions: Abnormal Uterine Bleeding, Abnormal Uterine Bleeding, Ovulatory Dysfunction, Abnormal Uterine Bleeding, Endometrial Hemostatic Dysfunction
Interventions: Levonorgestrel intrauterine system, Combined oral contraceptives; Device · Drug
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years to 51 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Vaginal Bleeding, Uterine Cramping
Interventions: Anticipatory Counseling, Cancer Screening Guidelines; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 178 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Los Angeles, California • Chicago, Illinois • Seattle, Washington

Conditions: Migraines, Bleeding, Spotting
Interventions: frovatriptan, placebo; Drug
Lead sponsor: Scott and White Hospital & Clinic; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Adenomyosis
Interventions: Vaginal Bromocriptine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 25 Years to 55 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Von Willebrand Disease, Type 1, Heavy Menstrual Bleeding
Interventions: Volta System; Device
Lead sponsor: Five Liters, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Post Partum Hemorrhage, Cesarean Section Complications, Blood Loss
Interventions: deuterated oxytocin (d5OT); Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Stanford, California • Chicago, Illinois

Conditions: Heavy Menstrual Bleeding
Interventions: Sparrow Link, Sparrow Link (Sham); Device
Lead sponsor: Spark Biomedical, Inc.; Industry
Eligibility: 14 Years to 45 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Leiomyoma, Uterine Fibroids, Uterine Neoplasms, Menorrhagia, Leiomyomatosis
Interventions: Uterine Fibroid Embolization (UFE), Contour SE™ Microspheres, Embosphere® Microspheres; Procedure · Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Safety and Effectiveness of the KOKO Device to Treat Primary Abnormal Postpartum Uterine Bleeding or Hemorrhage

Endometrial Cancer Vaginal Fluid Specimen Collection Study

Role of Blood Management in Perioperative Outcomes

Registry Study of Genesys HTA for Treatment of Menorrhagia

Postpartum Video Education

Prevention of Menstrual Migraines: Effects of Estrogen Add-back During the HFI in Patients Using Continuous Oral Contraceptives.

IV Ketorolac on Platelet Function Post-Cesarean Delivery

Coagulation Factor Changes Associated With Postpartum Hysterectomies

How Does Perimenopausal Menorrhagia Affect Women's Quality of Life and Cognitive Function?

Pivotal, Prospective, Multi-centre, Single-arm Study to Evaluate the Safety and Effectiveness of Oli for Identification of Patients, During the Intrapartum Period, Who Are at Higher Risk of Developing Abnormal Postpartum Uterine Bleeding, Including Postpartum Haemorrhage

Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia

Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users

Myomectomy vs Uterine Artery Embolization vs GnRh Antagonist for AUB-L

Postpartum Oxytocin Administration in the Era of Delayed Cord Clamping

Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery

Stopping Heavy Periods Project

Anticipatory Counseling on LNG-IUS Continuation, Utilization and Satisfaction

Prevention of Menstrual Migraines: Using Frovatriptan or Placebo During Hormone Free Intervals

Vaginal Bromocriptine for Treatment of Adenomyosis

Delivering Transcutaneous Auricular Neurostimulation to Reduce Heavy Menstrual Bleeding in Patients With and Without Von Willebrand Disease

Oxytocin Pharmacokinetics and Pharmacodynamics

Delivering tAN to Reduce HMB: The LUNA Study

A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE)